Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
AI-Spectral · NCT07446582
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 1000
- US sites recruiting
- 1
- Study start
- February 1, 2026
- Record last updated
- March 11, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old. The main questions it aims to answer are:
- Does DeepMSI AI detect AMD biomarkers with sensitivity equivalent to experienced clinicians?
- Does DeepMSI AI detect AMD biomarkers with specificity equivalent to experienced clinicians? Participants' eyes will be imaged by MSI-120 and their images will be analyzed for AMD biomarkers by both DeepMSI AI and retina specialists independently.
Researchers will compare retina image analysis from DeepMSI AI with ground truth (clinicians' interpretations) to see if AI achieves equivalency in sensitivity and specificity.
Being studied: Retina imaging device (MSI-120) and AI (DeepMSI AI)
Conditions: Age-Related (Dry) Macular Degeneration
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria: AMD subjects:
- Subjects over 40 years of age diagnosed for ne AMD
- Subject must be able to understand and must sign an IRB-approved ICF
- Subject must have minimum of one prior visit to the clinic
- Prior imaging must show signs of neAMD (e.g. drusen of different sizes and types with macular pigmentary changes, complete or incomplete retinal pigment epithelium and outer retinal atrophy) at least in one eye
Healthy subjects
- Subjects over 40 years of age have not been diagnosed with any type of AMD and prior imaging that shows no signs of AMD or other types of retinopathies.
- A minimum of light perception visual acuity is required to detect the fixation target during imaging.
- Two masked clinicians must confirm and categorize them into healthy eyes. -
Exclusion Criteria
- Assessed prior to any considerations of inclusion:
- Eyes with significant refractive media opacity (e.g. corneal opacity, significant cataract) that prevents adequate imaging
- Severe Refractive Error: Extreme high myopia (≥ -10.00D) or hyperopia (≥ +6.00D) that may compromise image quality.
- Unstable Ocular Conditions: Active ocular infections, severe uveitis, or status-post ocular trauma
- Recent Intraocular Surgery: Patients who have undergone intraocular surgery (e.g., cataract, retinal, or glaucoma surgery) within the past 3 months (except for intravitreal injections for GA therapy).
- History or Current Evidence of other types of retinopathy other than neAMD, e.g. Acute Retinal artery or Vein Occlusion, Diabetic Retinopathy, Idiopathic Epiretinal membrane, Myopic Maculopathy, Hypertension Retinopathy etc.
- History of Vitrectomy or Scleral Buckling for any kind of Vitreoretinopathy, e.g. Retinal Detachment, Epiretinal Membrane, Proliferative Diabetic Retinopathy etc. that could distort imaging results.
- Inability to Maintain Fixation: Including patients with advanced nystagmus, severe amblyopia, or cognitive impairments (dementia) affecting fixation stability.
- Severe Dry Eye or Ocular Surface Disease: Conditions that may interfere with imaging quality or patient comfort during the procedure.
- Subjects with essential tremor (head and neck tremors or unstable fixation to prevent adequate imaging)
- Inability to understand and refusal to sign informed consent
Recruiting US locations
Contact Lens & Vision
Woodbridge, NJ 07095
Site contact: John Cruz · 732-855-7950. · j.cruz.clvc@gmail.com
Study contacts (from the official record)
- Angela F. Esfandiarinezhad, PhD · 16135816702 · angela.f@deepmsi.com
- Emily Zhang, MD. PhD · EmilyZ@deepmsi.com
Similar studies in New Jersey
All healthy volunteers studies in New Jersey →- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Fair Lawn, NJ + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
Merck Sharp & Dohme LLC
- Location
- Marlton, NJ + 5 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Jersey City, NJ + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants
Harmony Biosciences Management, Inc.
- Location
- Eatontown, NJ
- Eligibility basics
- Ages 18–55